Search
Chlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]
L-tartaric acid
go.drugbank.com/drugs/DB09459ApprovedTartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics … , and is a dihydroxyl derivative of succinic acid.
Mixtures: SAL G., ENHOŞ MEYVE TUZU , 20 (SADE) ADETSynonyms: (+)-(R,R)-tartaric acid, (R,R)-Tartaric acidOxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigationalOxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. … [A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing
Products: Oxtellar XR, KALLION XRSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials … [A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. … DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.
Synonyms: (R)-crizotinibBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Perfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.
Polyethylene glycol 300
go.drugbank.com/drugs/DB11161ApprovedPolyethylene glycols are widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries. … It is a clear viscous liquid at room temperature with non-volatile, stable properties [A33116].
Categories: Compounds used in a research, industrial, or household settingTechnetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawn[A32115] The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues. … It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082]